Global X CleanTech vs Davita Inc — how do they compare? Global X CleanTech trades at $55.45 (market cap $24.57M), while Davita Inc trades at $175.04 (market cap $11.29B). The key difference: Davita Inc is far larger — about 459.5× Global X CleanTech's market cap, and Davita Inc is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and Davita Inc for 113 Days on average.
| CTEC | DVA | |
|---|---|---|
Market Cap | $24.57M | $11.29B |
Volume | 1,220 | 582,204 |
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $240.96 |
52-Week Low | $50.82 | $103.87 |
Typical Hold Time | 42 Days | 113 Days |
Enterprise Value | — | $24.01B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →